Go online to PeerView.com/JQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease. Upon completion of this activity, participants should be better able to: Cite the latest clinical evidence and guideline recommendations supporting the use of checkpoint inhibitors and other immunotherapy options for the management of HNC; Develop individualized treatment plans that incorporate checkpoint inhibitors and other immune modalities, including innovative combinational platforms, for the management of resectable, locally advanced, or recurrent/metastatic HNC; and Address practical aspects of care when using immunotherapy options, including provision of patient education and management of symptoms and immune-related AEs.